RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc.CTXR

Market cap
$90.67M
P/E ratio
Back to summarized table
Income statementBalance sheetCash flow
Sep 30,
2011		Sep 30,
2012		Sep 30,
2013		Sep 30,
2015		Sep 30,
2016		Sep 30,
2018		Sep 30,
2019		Sep 30,
2020		Sep 30,
2021		Sep 30,
2022
Cash and cash equivalents212135-676,137294,35198147042
Prepaid expenses---60,000598,48457,73248,111122,23733
Total Current Assets212135-736,137892,835108147345
Property and equipment, net----3,7421,4835901,5777,0234,100
Operating lease right-of-use asset, net-------986,204822,828646,074
Deposits----2,1672,16757,09357,09338,06238,062
In-process research and development-----1919195959
Goodwill----222999
Total Other Assets---5,401212121296969
Total Assets212135-741,53822312944142114
Accounts payable906-11,474559,150909,15623211
Accrued expenses3,9504,150-8,260958,101181,657246,225164,040621,9601
Accrued compensation----903,25011222
Operating lease liability-------158,999177,237196,989
Total Current Liabilities24,05345,98214,6941535445
Deferred tax liability-------556
Operating lease liability – non current-------855,471678,234481,245
Total Liabilities-------101011
Preferred stock - $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding----------
Common stock - $0.001 par value; 400,000,000 shares authorized; 146,211,130 and 145,979,429 shares issued and outstanding at September 30, 2022 and 2021, respectively18,00018,00018,00034,11873,13816,19928,93055,577145,979146,211
Additional paid-in capital--62,5228346880104228232
Accumulated deficit----9,040,549-17,336,247-40,257,838-55,819,982-70,593,867-96,047,821-129,688,467
Total Citius Pharmaceuticals, Inc. Stockholders’ Equity-23,841-45,847-14,694-635,21317282434133103
Non-controlling interest--------600,380600,380
Total Equity--------133103
Total Liabilities and Equity212135-741,53822312944142114